Literature DB >> 10074371

Unexpected metal ion requirements specific for catalysis of the branching reaction in a group II intron.

E Dème1, A Nolte, A Jacquier.   

Abstract

The splicing process catalyzed by group II intron ribozymes follows the same two-step pathway as nuclear pre-mRNA splicing. In vivo, the first splicing step of wild-type introns is a transesterification reaction giving rise to a branched lariat intron-3'-exon intermediate characteristic of this splicing mode. In the wild-type introns, the ribozyme core and the substrate intron-exon junctions are carried by the same precursor molecule, making it difficult to distinguish between RNA folding and catalysis under normal splicing reactions. To characterize the catalytic step of the first transesterification reaction, we studied the reversal of this reaction, reverse branching. In this reverse reaction, the excised lariat intron and the substrate 5'-exon can be preincubated and folded separately, allowing the measure of the catalytic rate of the reaction. To measure the catalytic rate of the second splicing step, purified lariat intron-3'-exon intermediate molecules were preincubated and folded prior to the addition of 5'-exon. Conditions could be found where chemistry appeared rate limiting for both catalytic steps. Study of the metal ion requirements under these conditions resulted in the unexpected finding that, for the intron studied, substitution of magnesium ions by manganese ions enhanced the rate of the first transesterification reaction by two orders of magnitude but had virtually no effect on the second transesterification reaction or the 5' splice site cleavage by hydrolysis. Finally, the catalytic rates measured under optimal conditions for both splicing steps were faster by three orders of magnitude in the branching pathway than in the hydrolytic pathway.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10074371     DOI: 10.1021/bi982462j

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  A three-dimensional perspective on exon binding by a group II self-splicing intron.

Authors:  M Costa; F Michel; E Westhof
Journal:  EMBO J       Date:  2000-09-15       Impact factor: 11.598

2.  A DEAD-box protein alone promotes group II intron splicing and reverse splicing by acting as an RNA chaperone.

Authors:  Sabine Mohr; Manabu Matsuura; Philip S Perlman; Alan M Lambowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-27       Impact factor: 11.205

3.  The linear form of a group II intron catalyzes efficient autocatalytic reverse splicing, establishing a potential for mobility.

Authors:  Michael Roitzsch; Anna Marie Pyle
Journal:  RNA       Date:  2009-01-23       Impact factor: 4.942

4.  DNA cleavage and reverse splicing of ribonucleoprotein particles reconstituted in vitro with linear RmInt1 RNA.

Authors:  María Dolores Molina-Sánchez; Nicolás Toro
Journal:  RNA Biol       Date:  2019-04-14       Impact factor: 4.652

5.  Metal ion catalysis during group II intron self-splicing: parallels with the spliceosome.

Authors:  E J Sontheimer; P M Gordon; J A Piccirilli
Journal:  Genes Dev       Date:  1999-07-01       Impact factor: 11.361

6.  Specific phosphorothioate substitution within domain 6 of a group II intron ribozyme leads to changes in local structure and metal ion binding.

Authors:  Michèle C Erat; Emina Besic; Michael Oberhuber; Silke Johannsen; Roland K O Sigel
Journal:  J Biol Inorg Chem       Date:  2017-12-07       Impact factor: 3.358

7.  MeRNA: a database of metal ion binding sites in RNA structures.

Authors:  Liliana R Stefan; Rui Zhang; Aaron G Levitan; Donna K Hendrix; Steven E Brenner; Stephen R Holbrook
Journal:  Nucleic Acids Res       Date:  2006-01-01       Impact factor: 16.971

8.  Activating the branch-forming splicing pathway by reengineering the ribozyme component of a natural group II intron.

Authors:  Dario Monachello; François Michel; Maria Costa
Journal:  RNA       Date:  2016-01-14       Impact factor: 4.942

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.